（文章来源：证券日报） 证券日报网讯技源集团11月25日在互动平台回答投资者提问时表示，截至2025年10月31日，公司的股东 人数为25700户。 ...

Core Viewpoint - The company has approved the use of idle raised funds for cash management, allowing for investment in low-risk financial products to enhance liquidity and returns [1]. Group 1: Fund Management Approval - The company’s board approved the use of up to 450 million yuan of idle raised funds for cash management, ensuring it does not affect the construction of investment projects [1]. - The approved financial products include structured deposits, agreed deposits, notice deposits, large certificates of deposit, and income certificates, with a maximum investment term of 12 months [1]. Group 2: Fund Utilization and Redemption - On August 21, 2025, the company utilized 125 million yuan of idle funds to purchase structured deposits from Ningbo Bank [2]. - The structured deposit matured on November 21, 2025, and the company successfully redeemed the principal of 125 million yuan along with a return of 630,136.99 yuan, which met expectations [2].

证券代码：603262 证券简称：技源集团 公告编号：2025-024 技源集团股份有限公司董事会 技源集团股份有限公司 2025年11月24日 关于使用闲置募集资金进行现金管理赎回的公告 | 受托方 | 产品名 | 金额 | 预期年化收 | 起息日 | 产品到期 | 本次赎 回（万元 | 本次收益 | | --- | --- | --- | --- | --- | --- | --- | --- | | 称 | | （万元） | 益率 | | 日 | ） | （元） | | 宁波银 | 结构性 存款 | 12,500 | 1.00%-2.00% | 2025.8.21 | 2025.11.21 | 12,500 | 630,136.99 | | 行 | | | | | | | | | 特此公告。 | | | | | | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 技源集团股份有限公司（以下简称"公司"）于2025年8月12日召开第二届董事 会第四次会议和第二届监事会第三次会议审议通过了《关于使用部分闲置募集资金 ...

Core Insights - The company, 技源集团, is a leading global supplier of HMB (β-Hydroxy β-Methylbutyrate), a crucial nutrient for muscle health, with a market share of approximately 65.80% in 2022 [1] - HMB is recognized for its unique ability to both increase muscle protein synthesis and reduce muscle protein breakdown, making it suitable for various sectors including sports nutrition, elderly health, weight management, and post-operative recovery [1] - The global demand for HMB is projected to grow, with estimated production volumes of 1,662.43 tons in 2023 and 1,758.50 tons in 2024, indicating a market share of around 52.27% and 53.34% for the company respectively [1] Financial Performance - For the first half of 2025, the company reported a revenue of 560 million yuan, representing a year-on-year growth of 15.65% [2] - Revenue from nutritional raw materials reached 390 million yuan, up 18.94%, while formulation product sales amounted to 170 million yuan, growing by 8.75% [2] - HMB sales specifically generated 158 million yuan, reflecting a growth of 3.75% [2] Market Development - The company maintains stable partnerships with major clients like Abbott while actively exploring new market opportunities and customer bases [2] - New HMB products are being developed for various applications, including adult milk powder for healthy aging and differentiated products for sports nutrition [2] - The company is also pursuing opportunities in pet nutrition and animal feed, collaborating with a large international agricultural enterprise [2]

Group 1 - The core viewpoint of the news is that 技源集团 (TechSource Group) experienced a decline in stock price and a net outflow in financing on November 17, with a trading volume of 36.29 million yuan and a financing balance of 65.33 million yuan, which represents 5.77% of its market capitalization [1] - As of September 30, the number of shareholders for TechSource Group decreased by 56.80% to 26,900, while the average circulating shares per person increased by 131.47% to 1,444 shares [2] - For the period from January to September 2025, TechSource Group reported a revenue of 797 million yuan, reflecting a year-on-year growth of 7.58%, while the net profit attributable to shareholders decreased by 14.72% to 117 million yuan [2] Group 2 - The main business of TechSource Group includes the research, innovation, and industrialization of dietary nutritional supplements, with revenue composition as follows: nutritional raw materials 34.70%, formulations 15.24%, and various specific nutritional raw materials and formulations contributing to the total [1]

Group 1 - The company approved the use of idle raised funds for cash management, with a total amount not exceeding 450 million yuan, to invest in low-risk financial products [1] - The investment products include structured deposits, agreement deposits, notice deposits, large certificates of deposit, and income certificates, with a maximum investment period of 12 months [1] - The funds can be used in a rolling manner within the approved amount and time frame [1] Group 2 - On August 15, 2025, the company used 100 million yuan of idle raised funds to purchase structured deposits from Shanghai Pudong Development Bank [2] - The structured deposit matured on November 14, 2025, and the company successfully redeemed the principal of 100 million yuan along with a return of 487,500 yuan, which met expectations [2]

Group 1 - The number of listed companies disclosing data is steadily increasing, indicating the maturation of China's nutrition and health industry [1] - Jiyuan Group shows considerable growth potential for HMB [1] - Minsheng Health is promoting stable growth in its mineral business through the synergy of online and offline channels [1] Group 2 - The third-quarter reports of seven major listed chain pharmacies have been released, revealing that Dazhenlin, Yifeng Pharmacy, Shuyapingmin, and Huaren Health achieved both revenue and net profit growth, while Laobaixing, Yixintang, and Jianzhijia experienced declines in both metrics [1] - The overall expansion speed of chain pharmacies has noticeably slowed, with a shift in focus from scale expansion to quality improvement and efficiency [1] - Specific performance data for the seven listed chain pharmacies for the first three quarters of the year includes: - Dazhenlin: Revenue of 20.068 billion, up 1.71%; Net profit of 1.081 billion, up 25.97% - Yifeng Pharmacy: Revenue of 17.286 billion, up 0.39%; Net profit of 1.225 billion, up 10.27% - Laobaixing: Revenue of 16.07 billion, down 1%; Net profit of 529 million, down 16.11% - Yixintang: Revenue of 13.001 billion, down 4.33%; Net profit of 269 million, down 8.17% - Jianzhijia: Revenue of 6.549 billion, down 2.80%; Net profit of 101 million, down 0.20% - Shuyapingmin: Revenue of 7.446 billion, up 5.19%; Net profit of 1.09 billion, up 927.37% - Huaren Health: Revenue of 3.892 billion, up 19.06%; Net profit of 157 million, up 45.21% [1] Group 3 - The trademark dispute involving Tongrentang is expected to come to an end as the acquisition of Tianjin Tongrentang Group's shares by Beijing Tongrentang Group has entered the acceptance stage, allowing Beijing Tongrentang to hold 60% of Tianjin Tongrentang [2] Group 4 - Six stores of Laobaixing in Loudi, Hunan Province were penalized for insurance fraud, where they switched health products for insurance-covered medications, leading to a fine and the revocation of their insurance service agreements [3]

证券代码：603262 证券简称：技源集团 公告编号：2025-023 技源集团股份有限公司（以下简称"公司"）于2025年8月12日召开第二届董事 会第四次会议和第二届监事会第三次会议审议通过了《关于使用部分闲置募集资金 进行现金管理的议案》，同意公司在不影响募集资金投资项目建设的情况下，使用 总额不超过45,000万元（含本数）的闲置募集资金进行现金管理，用于购买安全性 高、流动性好、低风险、稳健型的保本型理财产品（单项产品投资期限最长不超过 12个月，包括但不限于结构性存款、协定存款、通知存款、大额存单、收益凭证等)。 使用期限为自公司董事会审议通过之日起12个月内。在前述额度和期限范围内，资 金可循环滚动使用。详见公司于2025年8月13日披露的《关于使用部分闲置募集资金 进行现金管理的公告》（2025-007）。 2025年8月15日公司使用闲置募集资金10,000万元购买了浦发银行结构性存款。 2025年11月14日，公司购买的上述理财产品到期，公司已办理完成赎回手续，本金 10,000万元及收益487,500元均已归还至相应募集资金账户，收益符合预期。本次赎 回具体情况如下： | 受托方 | 产 ...

Group 1 - The core viewpoint of the news is that 技源集团 (TechSource Group) has shown a slight increase in stock price and has engaged in financing activities, indicating investor interest despite a decrease in net profit year-on-year [1][2]. Group 2 - On November 14, TechSource Group's stock rose by 0.20%, with a trading volume of 32.64 million yuan. The financing buy-in amount for the day was 3.56 million yuan, while the net financing buy-in was 1.27 million yuan, leading to a total financing and margin balance of 68.84 million yuan [1]. - As of November 14, the financing balance of TechSource Group accounted for 6.03% of its market capitalization, indicating a moderate level of leverage [1]. - The company is based in Shanghai and specializes in the research, innovation, and industrialization of dietary nutritional supplements, with a revenue composition that includes 34.70% from nutritional raw materials and 15.24% from formulations [1]. Group 3 - As of September 30, the number of shareholders for TechSource Group was 26,900, a decrease of 56.80% from the previous period, while the average circulating shares per person increased by 131.47% to 1,444 shares [2]. - For the period from January to September 2025, TechSource Group reported a revenue of 797 million yuan, reflecting a year-on-year growth of 7.58%, but the net profit attributable to shareholders decreased by 14.72% to 117 million yuan [2].

Core Viewpoint - The company plans to hold an investor briefing on November 27, 2025, to discuss its Q3 2025 financial results and address investor inquiries [2][3][6]. Group 1: Meeting Details - The investor briefing is scheduled for November 27, 2025, from 16:00 to 17:00 [2][6]. - The meeting will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [2][3][6]. - Investors can submit questions from November 17 to November 26, 2025, through the Roadshow Center website or via the company's email [2][5]. Group 2: Company Representatives - The meeting will feature key company representatives, including Chairman Jingshi Joe Zhou, General Manager Long Ling, and Financial Director Wang Yan [4]. - The attendance of specific personnel may vary due to unforeseen circumstances [4]. Group 3: Contact Information - For inquiries, investors can contact Wang Yan at phone number 021-64954866 or via email at ir@cn.tsigroupltd.com [7]. - After the briefing, the main content and details of the meeting will be available on the Roadshow Center website [7].